ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026

ADC Therapeutics SA

2024-Q2 EPS reported -$0.93 revenue$35,463,000

ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.
Net loss $36.5M ($0.38/sh) vs $48.9M ($0.60/sh) in Q2 2023; adjusted net loss $24.4M ($0.25/sh).
Cash $300.1M after $97.4M May 2024 offering; runway extended into mid-2026.
LOTIS-5 Phase 3 IDMC recommended continue; full enrollment expected before year-end 2024.
LOTIS-7 dose expansion on track; safety/efficacy data expected year-end 2024, mature data H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.